ERD

Transwell migration assay to interrogate human CAR-T cell chemotaxis

Project: ARMOR-T

Updated at: 28-06-2024

Show more information

Project acronym ARMOR-T

CXCR6 deficiency impairs cancer vaccine efficacy and CD8+ resident memory T-cell recruitment in head and neck and lung t...

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Challenges in Clinical Trial Design for T Cell‐Based Cancer Immunotherapy

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

CAR T cell therapy in solid tumors: a short review.

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis V...

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Lung emphysema and impaired macrophage elastase clearance in mucolipin 3 deficient mice

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or ...

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-t...

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Teaching an old dog new tricks: next-generation CAR T cells

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibo...

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Long non-coding RNAs in cancer stem cells

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Interleukins in cancer: from biology to therapy

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodg...

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Innate and adaptive immunity combined for cancer treatment

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Cancer cells induce interleukin-22 production from memory CD4 + T cells via interleukin-1 to promote tumor growth

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasi...

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the rec...

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Advances in cancer immunotherapy 2019 – latest trends

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Targeting interleukin-22 for cancer therapy

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

A modular and controllable T cell therapy platform for acute myeloid leukemia

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Therapeutic Strategies for Targeting IL-1 in Cancer.

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Periodic Reporting for period 3 - ARMOR-T (Armoring multifunctional T cells for cancer therapy)

Project: ARMOR-T

Updated at: 27-04-2024

Show more information

Project acronym ARMOR-T

Resources

Selected filters:

Transwell migration assay to interrogate human CAR-T cell chemotaxis

CXCR6 deficiency impairs cancer vaccine efficacy and CD8+ resident memory T-cell recruitment in head and neck and lung t...

Challenges in Clinical Trial Design for T Cell‐Based Cancer Immunotherapy

CAR T cell therapy in solid tumors: a short review.

Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma

Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis V...

Lung emphysema and impaired macrophage elastase clearance in mucolipin 3 deficient mice

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or ...

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy

CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-t...

Teaching an old dog new tricks: next-generation CAR T cells

The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors

Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1

Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibo...

Long non-coding RNAs in cancer stem cells

Interleukins in cancer: from biology to therapy

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodg...

Innate and adaptive immunity combined for cancer treatment

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

Cancer cells induce interleukin-22 production from memory CD4 + T cells via interleukin-1 to promote tumor growth

Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasi...

Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy

Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the rec...

Advances in cancer immunotherapy 2019 – latest trends

Targeting interleukin-22 for cancer therapy

A modular and controllable T cell therapy platform for acute myeloid leukemia

Therapeutic Strategies for Targeting IL-1 in Cancer.

Periodic Reporting for period 3 - ARMOR-T (Armoring multifunctional T cells for cancer therapy)